Antibiotics Market to Notice Prominent Growth of USD 49.8 billion by 2030, Size, Share, Trends, Demand and Industry Growth

Antibiotics Market Snapshot

“The Antibiotics Market is estimated to increase at a CAGR of 4.56% from $ 42.9 Billion in 2023 to $ 49.8 billion by 2030.”

Antibiotics are used to treat and prevent certain types of bacterial infections by eradicating or stopping their spread, but not all individuals can benefit from them. Colds, flu, and most coughs are viral diseases that cannot be treated with antibiotics.

Antibiotics work by reducing the production of harmful bacteria and viruses.

Antibiotics work by eliminating germs or preventing their growth. They eliminate essential components like DNA or cell walls, and halt bacterial development by preventing the production of certain proteins needed for reproduction.

The correct use of antibiotics is crucial for their intended function and to alleviate symptoms.

Your doctor will provide exact instructions on antibiotic dosage, including the duration of therapy, daily dosage, and dietary restrictions. They will also clarify the frequency and dietary restrictions. If you encounter any confusion, consult your doctor.

Antibiotics should only be used for the specific infection prescribed, as they are not suitable for future use and may not be beneficial in the future.

Avoid taking prescribed medication, as prescriptions are custom-made for each individual based on their illness, medical history, and allergies, similar to clothing made to order, and should not be taken for someone else.

Discard unneeded medication discreetly, ensuring you receive the correct dosage. Consult a chemist for extra medication disposal.

>>>Download Sample Report Now: https://marketreportservice.com/request-sample/antibiotics-market-54556  

Why is it important to take antibiotics only when they're needed?

Antibiotics can cause negative side effects and increase antibiotic resistance, indicating the development of microorganisms that can withstand their effects, indicating the ongoing growth of germs. Therefore, only use them when necessary.

How do I use antibiotics correctly?

• Always pay close attention to the instructions. Even if you feel better, finish the medication. Some germs could survive if you stop taking them too soon and re-infect you.
• Don't put off taking your antibiotics.
• Don't give people your antibiotic.
• Antibiotics prescribed for someone else should not be taken. This might put off the finest medical care for you, make you worse, or have other impacts.

Growth Drivers

The rapid spread of the pandemic significantly impacted the antibiotics market, leading to increased demand and attractive insurance company reimbursement plans. The rapid outcomes of new antibiotics from leading manufacturers drove market expansion. However, as modern medicine advances, the number of adverse effects has decreased, allowing patients to trust the system and opt for antibiotics as a treatment option. Overall, the rapid growth of the antibiotics market is a testament to the importance of antibiotics in healthcare.

The item pipeline is expected to benefit from increasing public-private partnerships, where governmental organizations provide funding and innovative R&D strategies to antibiotics-developing companies.

The global demand for antibiotics is expected to drive market expansion, as they treat bacterial infections in humans and animals. The Lancet Regional Health-Southeast Asia study revealed that cefixime 200 mg tablet (6.5%) and azithromycin 500 mg tablet (7.6%) are the most commonly used antibiotic formulations in India, indicating a growing global demand for these drugs.

Market Restraints

Antibiotic resistance, time-consuming administrative procedures, and challenges from antibiotics and self-prescription are expected to slow market expansion during the speculative phase.

Antibiotic resistance and rising medication endorsement prices are expected to hinder industry growth.

Antibiotics Market Segment Analysis

Antibiotics Market by Drug class

The penicillin antibiotic has seen the highest increase among drug classes due to its rapid market supply and sales. Its widespread use contributes to the global demand for this class of drugs. South Korea, Italy, Spain, and Hong Kong are the top markets for penicillin antibiotics, as they use significant amounts of both narrow and broad spectrum medications.

Antibiotics, including cephalosporin, tetracycline, microlides, suifonamides, fluoroquinolones, and aminoglycosides, have significantly benefited the antibiotic market due to their international expansion due to the rising rate of chronic conditions among the population.

The cephalosporins market is expected to experience significant growth in the forecast period, a beta-lactam antibiotic used to treat gram-positive and gram-negative bacterial infections, including upper respiratory tract infections, meningitis, skin infections, and pneumonia.

Antibiotics Market by Application

The market is divided into skin, respiratory, gastrointestinal, ear, septicemia, and urinary tract infections based on application. Respiratory infections have seen the greatest increase due to global pollution and climate change. The pandemic has severely impacted people's respiratory systems, making it a market-driving factor. The number of patients suffering from respiratory illnesses has also increased.

The military system's limitations are impacting respiratory organs, leading to a rising demand for medications to treat respiratory conditions. The market for antibiotics is expected to increase, with the urinary tract infection segment being the largest category with the highest demand and supply.

Competitive Landscape of the Antibiotics Market Analysis

• Merck & Co., Inc.
• Allergan plc (AbbVie)
• GlaxoSmithKline plc.
• Pfizer Inc.
• Novartis AG
• Sanofi S.A.
• AstraZeneca plc
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Eli Lilly and Company
• Bayer AG
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Astellas Pharma Inc.
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Company, Limited
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited.

New Developments in Antibiotics Market

15 April 2023, Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years.

GSK plc, presented positive results from the pivotal EAGLE-2 and EAGLE-3 phase III trials for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urinary tract infections (uUTI) in female adults and adolescents. The data were disclosed today in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark.

In October 2021, Sandoz acquired GSK's cephalosporin antibiotics business. It now has the rights to three well-known brands (Zinnat, Zinacef, and Fortum) in 100 markets, strengthening its position as the world's leading antibiotics company.

 Regional Analysis

Largest Market-> North America

Fastest Growing Market-> Asia Pacific

North America is expected to dominate the market due to rising healthcare spending and the prevalence of infectious illnesses. Antibiotics treat bacteria-related infections, killing germs or preventing their growth. The U.S. government is implementing programs like R&D projects and antibiotic stewardship to manage infectious illnesses, aiming to achieve the largest market share among other regions.

The CDC report from October 2022 shows that in the US, over 7,174 new TB cases were documented in 2021, with Hispanic or Latino people having the highest prevalence. This high frequency of infectious illnesses is expected to increase demand for antibiotics, fueling market expansion. Factors influencing the growth of the antibiotics market in the US include the frequency of illnesses, important product releases, large concentrations of market participants or manufacturers, acquisitions, and collaborations among significant companies.

In 2022, Asia Pacific exhibited the fastest growing market share, driven by increased antibiotic use, incurable diseases, and government initiatives. The territorial market is also expanding due to traditional companies. India and China are the largest antibiotic markets in the region, driven by unregulated transactions and excessive antibiotic usage. The growth is expected to continue over the projected period.

Segments Covered in the Antibiotics Market Report

Antibiotics Market Analysis by Drug class

• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolide
• Carbapenem
• Aminoglycoside
• Sulfonamide
• 7-ACA
• Others

Antibiotics Market Analysis by Action Mechanism

• Cell Wall Synthesis
• Protein Synthesis
• DNA Synthesis
• RNA Synthesis
• Mycolic Acid
• Others

Frequently Asked Questions

What is the expected growth rate of the Antibiotics market over the next 7 years?

Antibiotics Market is estimated to increase at a CAGR of 4.56% from $ 42.9 Billion in 2023 to $ 49.8 billion by 2030.

Who are the major players in the Antibiotics market and what is their market share?

Merck & Co., Inc.,Allergan plc (AbbVie),GlaxoSmithKline plc.,Pfizer Inc.,Novartis AG,Sanofi S.A.,AstraZeneca plc,Johnson & Johnson,Teva Pharmaceutical Industries Ltd.,Mylan N.V.,Eli Lilly and Company,Bayer AG,Bristol-Myers Squibb Company, are prominent players operating and dominating in the market.

What is the demand projection for Antibiotics by 2030?

Demand for cooking sauce is projected to reach a market value of US$ 49.8 billion by 2030-end.

What is the sales growth projection for Antibiotics?

Revenue from sales of Antibiotics is projected to increase at a CAGR of 4.56% through 2030.

1. EXECUTIVE SUMMARY
2. INTRODUCTION
   2.1. Overview of Antibiotics
   2.2. Characteristics of an Ideal Antibiotic
   2.3. Advantages of Antibiotics
   2.4. Classification of Antibiotics
   2.5. History of Antibiotics
   2.6. Innovations in Antibiotics
   2.7. Mechanism of Action of Antibiotics
   2.8. Challenges associated with the use of Antibiotics
   2.9. Future Perspectives
3. MARKET LANDSCAPE: APPROVED ANTIBIOTIC GENERICS
   3.1. Approved Antibiotic Generics: Overall Market Landscape
   3.1.1. Analysis by Year of Approval
   3.1.2. Analysis by Region(s) of Approval
   3.1.4. Analysis by Type of Antibiotic (based on Chemical Structure)
   3.1.3. Analysis by Type of Antibiotic (based on Drug Class)
   3.1.5. Analysis by Mechanism of Action
   3.1.6. Analysis by Spectrum of Activity
   3.1.7. Analysis by Type of Target Bacteria(s)
   3.1.8. Analysis by Target Bacterial Strain(s)
   3.1.9. Analysis by Target Disease Indication(s)
   3.1.10. Analysis by Nature of Source
   3.1.11. Analysis by Type of Therapy
   3.1.12. Analysis by Route(s) of Administration
   3.1.13. Analysis by Dosage Form(s)
   3.1.14. Analysis by Type of Patient Population (based on Age)
   3.1.15. Analysis by Type of Patient Population (based on Gender)

3.2. Approved Antibiotic Generics: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Analysis by Location of Headquarters
3.2.4. Most Active Players: Analysis by Number of Approved Generics

4. MARKET LANDSCAPE: APPROVED ANTIBIOTIC BRANDS
   4.1. Approved Antibiotic Brands: Overall Market Landscape
   4.1.1. Analysis by Year of Approval
   4.1.2. Analysis by Region(s) of Approval
   4.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
   4.1.4. Analysis by Type of Antibiotic (based on Drug Class)
   4.1.5. Analysis by Mechanism of Action
   4.1.6. Analysis by Spectrum of Activity
   4.1.7. Analysis by Type of Target Bacteria
   4.1.8. Analysis by Target Bacterial Strain(s)
   4.1.9. Analysis by Target Disease Indication(s)
   4.1.10. Analysis by Nature of Source
   4.1.11. Analysis by Type of Therapy
   4.1.12. Analysis by Route(s) of Administration
   4.1.13. Analysis by Dosage Form(s)
   4.1.14. Analysis by Type of Patient Population (based on Age)
   4.1.15. Analysis by Type of Patient Population (based on Gender)
   4.1.16. Analysis by Type of Innovation

4.2. Approved Antibiotic Brands: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.4. Analysis by Location of Headquarters
4.2.5. Most Active Players: Analysis by Number of Approved Brands

5. MARKET LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS
   5.1. Clinical -Stage Antibiotics: Overall Market Landscape
   5.1.1. Analysis by Status of Development
   5.1.2. Analysis by Stage of Development
   5.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
   5.1.4. Analysis by Type of Antibiotic (based on Drug Class)
   5.1.5. Analysis by Mechanism of Action
   5.1.6. Analysis by Spectrum of Activity
   5.1.7. Analysis by Type of Target Bacteria(s)
   5.1.8. Analysis by Target Bacterial Strain(s)
   5.1.9. Analysis by Target Disease Indication(s)
   5.1.10. Analysis by Therapeutic Area(s)
   5.1.11. Analysis by Nature of Source
   5.1.12. Analysis by Type of Therapy
   5.1.13. Analysis by Route(s) of Administration
   5.1.14. Analysis by Dosage Form(s)
   5.1.15. Analysis by Dosage Strength
   5.1.16. Analysis by Dosage Frequency
   5.1.17. Analysis by Dosing Period
   5.1.18. Analysis by Type of Patient Population (based on Age)
   5.1.19. Analysis by Type of Patient Population (based on Gender)
   5.1.20. Analysis by Special Designation Received

5.2. Clinical -Stage Antibiotics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Most Active Players: Analysis by Number of Clinical-stage Antibiotics
5.2.5. Most Active Players: Analysis by Number of Preclinical-stage Antibiotics

6. COMPANY PROFILES
   6.1. Bristol-Myers Squibb
   6.1.1. Company Overview
   6.1.2. Key Executives
   6.1.3. Financial Information
   6.1.4. Product Portfolio
   6.1.5. Recent Developments
   6.1.6. Key Strategies
   6.1.7. Key Focus Areas
   6.1.8. Expert Opinion

6.2. Daiichi Sankyo
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments
6.2.6. Key Strategies
6.2.7. Key Focus Areas
6.2.8. Expert Opinion

6.3. GlaxoSmithKline
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments
6.3.6. Key Strategies
6.3.7. Key Focus Areas
6.3.8. Expert Opinion

6.4. Melinta Therapeutics
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Financial Information
6.4.4. Product Portfolio
6.4.5. Recent Developments
6.4.6. Key Strategies
6.4.7. Key Focus Areas
6.4.8. Expert Opinion

6.5. Merck
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments
6.5.6. Key Strategies
6.5.7. Key Focus Areas
6.5.8. Expert Opinion

6.6. Pfizer
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments
6.6.6. Key Strategies
6.6.7. Key Focus Areas
6.6.8. Expert Opinion

6.7. Concluding Remarks

7. PARTNERSHIPS AND COLLABORATIONS ANALYSIS
   7.1. Partnership Models
   7.2. Antibiotics: List of Partnerships and Collaborations
   7.2.1. Analysis by Year of Partnership
   7.2.2. Analysis by Type of Partnership
   7.2.3. Analysis by Type of Partner
   7.2.4. Analysis by Company Size
   7.2.5. Local and International Agreements
   7.2.6. Intracontinental and Intercontinental Agreements
   7.2.7. Most Active Players: Analysis by Number of Partnerships
   7.2.8. Concluding Remarks
8. CLINICAL TRIAL ANALYSIS
   8.1. Analysis Methodology and Key Parameters
   8.2. Antibiotics: Clinical Trial Analysis
   8.2.1. Analysis by Trial Registration Year
   8.2.2. Analysis by Trial Status
   8.2.3. Analysis by Trial Phase
   8.2.4. Analysis by Type of Patient Population (based on Gender)
   8.2.5 Word Cloud Analysis: Key Focus Areas
   8.2.6. Analysis by Type of Sponsor
   8.2.7. Analysis by Geography
   8.2.8. Most Active Industry Players: Analysis by Number of Trials
   8.2.9. Most Active Non-Industry Players: Analysis by Number of Trials
9. KEY OPINION LEADERS
   9.1. Assumptions and Key Parameters
   9.2. Methodology
   9.3. Antibiotics: Key Opinion Leaders (KOLs)
   9.3.1. Analysis by Type of KOL
   9.3.2. Analysis by Qualification
   9.3.3. Analysis by Type of Organization
   9.3.4. Analysis by Affiliated Organization
   9.3.5. Analysis by Geographical Location of KOLs
   9.3.6. Analysis by Target Disease Indication(s)
   9.3.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
   9.3.8 Most Prominent KOLs: Peer Group 2 (Other Types of Investigators)
   9.3.9. Most Prominent KOLs: Analysis by RA score
   9.3.10. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
   9.3.11. Concluding Remarks
10. KEY TRENDS IN ANTIBIOTICS INDUSTRY
    10.1. Antibiotics Industry: Drug-Pricing Analysis
    10.2. Antibiotics Industry: Outsourcing Trends
    10.3. Antibiotics Industry: Impact of COVID-19
11. APPROVED ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS
    11.1. Chapter Overview
    11.2. Methodology
    11.3. Success Protocol Analysis of Recently Approved Antibiotic Brands
    11.3.1. Dovprela (TB Alliance)
    11.3.1.1. Drug Overview
    11.3.1.2. Success Protocol Analysis

11.3.2. Fetroja (Shionogi)
11.3.2.1. Drug Overview
11.3.2.2. Success Protocol Analysis

11.3.4. Kimyrsa (Melinta Therapeutics)
11.3.4.1. Drug Overview
11.3.4.2. Success Protocol Analysis

11.3.5 Recarbrio (Merck)
11.3.5.1. Drug Overview
11.3.5.2. Success Protocol Analysis

11.3.6. Quofenix (Menarini)
11.3.6.1. Drug Overview
11.3.6.2. Success Protocol Analysis

11.3.9 Xenleta (Nabriva Therapeutics)
11.3.9.1. Drug Overview
11.3.9.2. Success Protocol Analysis

11.4. Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
    12.1. Chapter Overview
    12.2. Key Assumptions and Methodology
    12.3. Global Antibiotics Market, 2023-2030
    12.3.1. Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2030
    12.3.1.1. Antibiotics Market for Aminoglycosides, 2023-2030
    12.3.1.2. Antibiotics Market for Cephalosporins, 2023-2030
    12.3.1.3. Antibiotics Market for Fluoroquinolones, 2023-2030
    12.3.1.4. Antibiotics Market for Macrolides, 2023-2030
    12.3.1.5. Antibiotics Market for Oxazolidinones, 2023-2030
    12.3.1.6. Antibiotics Market for Penicillins, 2023-2030
    12.3.1.7. Antibiotics Market for Sulphonamides, 2023-2030
    12.3.1.8. Antibiotics Market for Tetracyclines, 2023-2030
    12.3.1.9. Antibiotics Market for Other Classes, 2023-2030

12.3.2. Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2030
12.3.2.1. Antibiotics Market for Bacterial Infections, 2023-2030
12.3.2.2. Antibiotics Market for Dermatological/ Skin Infections, 2023-2030
12.3.2.3. Antibiotics Market for Gastrointestinal Infections, 2023-2030
12.3.2.4. Antibiotics Market for Hematological Infections, 2023-2030
12.3.2.5. Antibiotics Market for Nephrological Infections, 2023-2030
12.3.2.6. Antibiotics Market for Pulmonary Infections, 2023-2030
12.3.2.7. Antibiotics Market for Reproductive Tract Infections, 2023-2030
12.3.2.8. Antibiotics Market for Respiratory Tract Infections, 2023-2030
12.3.2.9. Antibiotics Market for Sexually Transmitted Diseases, 2023-2030
12.3.2.10. Antibiotics Market for Urinary Tract Infections, 2023-2030
12.3.2.11. Antibiotics Market for Other Bacterial Infections, 2023-2030

12.3.3. Antibiotics Market: Distribution by Type of Therapy, 2023 and 2030
12.3.3.1. Antibiotics Market for Monotherapies, 2023-2030
12.3.3.2. Antibiotics Market for Combination Therapies, 2023-2030

12.3.4. Antibiotics Market: Distribution by Route of Administration, 2023 and 2030
12.3.4.1. Antibiotics Market for Intravenous Therapies, 2023-2030
12.3.4.2. Antibiotics Market for Oral Therapies, 2023-2030

12.3.5. Antibiotics Market: Distribution by Geography, 2023 and 2030
12.3.5.1. Antibiotics Market in North America, 2023-2030
12.3.5.2. Antibiotics Market in Europe, 2023-2030
12.3.5.2. Antibiotics Market in Asia-Pacific, 2023-2030
12.3.5.3. Antibiotics Market in Rest of the World, 2023-2030

12.3.6. Sales Forecast: Approved Antibiotics
12.3.6.1. Aemcolo®: Sales Forecast, 2023-2030
12.3.6.2. Arikayce®: Sales Forecast, 2023-2030
12.3.6.3. Baxdela™: Sales Forecast, 2023-2030
12.3.6.4. Dalacin C: Sales Forecast, 2023-2030
12.3.6.5. Dovprela®: Sales Forecast, 2023-2030
12.3.6.6. Emrok: Sales Forecast, 2023-2030
12.3.6.7. Emrok-O: Sales Forecast, 2023-2030
12.3.6.8. Fetroja®: Sales Forecast, 2023-2030
12.3.6.9. Kimyrsa™: Sales Forecast, 2023-2030
12.3.6.10. Lasvic®: Sales Forecast, 2023-2030
12.3.6.11. Nuzyra®: Sales Forecast, 2023-2030
12.3.6.12. Orbactiv™/Tenkasi: Sales Forecast, 2023-2030
12.3.6.13. Ozanex™: Sales Forecast, 2023-2030
12.3.6.14. Quofenix: Sales Forecast, 2023-2030
12.3.6.15. Recarbrio™: Sales Forecast, 2023-2030
12.3.6.16. Seysara™: Sales Forecast, 2023-2030
12.3.6.17. Solosec®: Sales Forecast, 2023-2030
12.3.6.18. Vabomere™: Sales Forecast, 2023-2030
12.3.6.19. Xenleta™: Sales Forecast, 2023-2030
12.3.6.20. XEPI™: Sales Forecast, 2023-2030
12.3.6.21. Xerava™: Sales Forecast, 2023-2030
12.3.6.22. Xydalba®: Sales Forecast, 2023-2030
12.3.6.23. Youxitai: Sales Forecast, 2023-2030
12.3.6.24. Zemdri™: Sales Forecast, 2023-2030
12.3.6.25. Zerbaxa®: Sales Forecast, 2023-2030
12.3.6.26. Zyvoxam®: Sales Forecast, 2023-2030

12.3.7. Sales Forecast: Clinical-stage Antibiotics
12.3.7.1. Cefepime-Taniborbactam: Sales Forecast, 2023-2030
12.3.7.2. CONTEPO™: Sales Forecast, 2023-2030
12.3.7.3. Gepotidacin (GSK2140944): Sales Forecast, 2023-2030
12.3.7.4. MBK-01: Sales Forecast, 2023-2030
12.3.7.5. MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2030
12.3.7.6. Nafithromycin (WCK 4873): Sales Forecast, 2023-2030
12.3.7.7. RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, 2023-2030
12.3.7.8. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2030
12.3.7.9. Ridinilazole (SMT 19969): Sales Forecast, 2023-2030
12.3.7.10. Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2030
12.3.7.11. Tebipenem HBr: Sales Forecast, 2023-2030
12.3.7.12. WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2030
12.3.7.13. WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2030
12.3.7.14. XNW4107 (Funobactam): Sales Forecast, 2023-2030
12.3.7.15. Zabofloxacin: Sales Forecast, 2023-2030
12.3.7.16. Zoliflodacin (ETX0914): Sales Forecast, 2023-2030

13. APPENDIX I: TABULATED DATA
14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 1.1 Executive Summary: Overall Market Landscape of Approved Antibiotic Generics
Figure 1.2 Executive Summary: Overall Market Landscape of Approved Antibiotic Brands
Figure 1.3 Executive Summary: Overall Market Landscape of Clinical -Stage Antibiotics
Figure 1.4 Executive Summary: Partnerships and Collaborations
Figure 1.5 Executive Summary: Clinical Trial Analysis
Figure 1.6 Executive Summary: Key Opinion Leaders
Figure 1.7 Executive Summary: Market Forecast and Opportunity Analysis
Figure 2.1 Classification of Antibiotics
Figure 2.2 History of Antibiotics
Figure 2.3 Mechanism of Action of Antibiotics
Figure 3.1 Approved Antibiotic Generics: Distribution by Year of Approval
Figure 3.2 Approved Antibiotic Generics: Distribution by Region(s) of Approval
Figure 3.3 Approved Antibiotic Generics: Distribution by Year and Region(s) of Approval
Figure 3.4 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 3.5 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Drug Class)
Figure 3.6 Approved Antibiotic Generics: Distribution by Mechanism of Action
Figure 3.7 Approved Antibiotic Generics: Distribution by Spectrum of Activity
Figure 3.8 Approved Antibiotic Generics: Distribution by Type of Target Bacteria(s)
Figure 3.9 Approved Antibiotic Generics: Distribution by Target Bacterial Strain(s)
Figure 3.10 Approved Antibiotic Generics: Distribution by Target Disease Indication(s)
Figure 3.11 Approved Antibiotic Generics: Distribution by Nature of Source
Figure 3.12 Approved Antibiotic Generics: Distribution by Type of Therapy
Figure 3.13 Approved Antibiotic Generics: Distribution by Route(s) of Administration
Figure 3.14 Approved Antibiotic Generics: Distribution by Dosage Form(s)
Figure 3.15 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Age)
Figure 3.16 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Gender)
Figure 3.17 Approved Antibiotic Generic Developers: Distribution by Year of Establishment
Figure 3.18 Approved Antibiotic Generic Developers: Distribution by Company Size
Figure 3.19 Approved Antibiotic Generic Developers: Distribution by Location of Headquarters
Figure 3.20 Most Active Players: Distribution by Number of Approved Generics
Figure 4.1 Approved Antibiotic Brands: Distribution by Year of Approval
Figure 4.2 Approved Antibiotic Brands: Distribution by Region(s) of Approval
Figure 4.3 Approved Antibiotic Brands: Distribution by Year and Region(s) of Approval
Figure 4.4 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 4.5 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Drug Class)
Figure 4.6 Approved Antibiotic Brands: Distribution by Mechanism of Action
Figure 4.7 Approved Antibiotic Brands: Distribution by Spectrum of Activity
Figure 4.8 Approved Antibiotic Brands: Distribution by Type of Target Bacteria(s)
Figure 4.9 Approved Antibiotic Brands: Distribution by Target Bacterial Strain(s)
Figure 4.10 Approved Antibiotic Brands: Distribution by Target Disease Indication(s)
Figure 4.11 Approved Antibiotic Brands: Distribution by Nature of Source
Figure 4.12 Approved Antibiotic Brands: Distribution by Type of Therapy
Figure 4.13 Approved Antibiotic Brands: Distribution by Route(s) of Administration
Figure 4.14 Approved Antibiotic Brands: Distribution by Dosage Form(s)
Figure 4.15 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Age)
Figure 4.16 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Gender)
Figure 4.17 Approved Antibiotic Brands: Distribution by Type of Innovation
Figure 4.18 Approved Antibiotic Brand Developers: Distribution by Year of Establishment
Figure 4.19 Approved Antibiotic Brand Developers: Distribution by Company Size
Figure 4.20 Approved Antibiotic Brand Developers: Distribution by Location of Headquarters
Figure 4.21 Most Active Players: Distribution by Number of Approved Brands
Figure 5.1 Clinical -Stage Antibiotics: Distribution by Status of Development
Figure 5.2 Clinical -Stage Antibiotics: Distribution by Stage of Development
Figure 5.3 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Chemical Structure)
Figure 5.4 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Drug Class)
Figure 5.5 Clinical -Stage Antibiotics: Distribution by Mechanism of Action
Figure 5.6 Clinical -Stage Antibiotics: Distribution by Spectrum of Activity
Figure 5.7 Clinical -Stage Antibiotics: Distribution by Type of Target Bacteria(s)
Figure 5.8 Clinical -Stage Antibiotics: Distribution by Target Bacterial Strain(s)
Figure 5.9 Clinical-Stage Antibiotics: Distribution by Target Disease Indication(s)
Figure 5.10 Clinical -Stage Antibiotics: Distribution by Therapeutic Area(s)
Figure 5.11 Clinical -Stage Antibiotics: Distribution by Nature of Source
Figure 5.12 Clinical -Stage Antibiotics: Distribution by Type of Therapy
Figure 5.13 Clinical -Stage Antibiotics: Distribution by Route(s) of Administration
Figure 5.14 Clinical -Stage Antibiotics: Distribution by Dosage Form(s)
Figure 5.15 Clinical -Stage Antibiotics: Distribution by Dosage Strength
Figure 5.16 Clinical -Stage Antibiotics: Distribution by Dosage Frequency
Figure 5.17 Clinical -Stage Antibiotics: Distribution by Dosing Period
Figure 5.18 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Age)
Figure 5.19 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Gender)
Figure 5.20 Clinical -Stage Antibiotics: Distribution by Special Designation Received
Figure 5.21 Clinical -Stage Antibiotic Developers: Distribution by Year of Establishment
Figure 5.22 Clinical -Stage Antibiotic Developers: Distribution by Company Size
Figure 5.23 Clinical -Stage Antibiotic Developers: Distribution by Location of Headquarters
Figure 5.24 Most Active Players: Analysis by Number of Clinical-stage Antibiotics
Figure 5.25 Most Active Players: Analysis by Number of Preclinical-stage Antibiotics
Figure 6.1 Bristol-Myers Squibb: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.2 Bristol-Myers Squibb: Key Strategies
Figure 6.3 Bristol-Myers Squibb: Key Focus Areas
Figure 6.4 Daiichi Sankyo: Annual Revenues, 2017-9M 2022 (JPY Billion)
Figure 6.5 Daiichi Sankyo: Key Strategies
Figure 6.6 Daiichi Sankyo: Key Focus Areas
Figure 6.7 GlaxoSmithKline: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.8 GlaxoSmithKline: Key Strategies
Figure 6.9 GlaxoSmithKline: Key Focus Areas
Figure 6.10 Melinta Therapeutics: Annual Revenues, 2017-6M 2019 (USD Billion)
Figure 6.11 Melinta Therapeutics: Key Strategies
Figure 6.12 Melinta Therapeutics: Key Focus Areas
Figure 6.13 Merck: Annual Revenues, 2017-2022 (USD Billion)
Figure 6.14 Merck: Key Strategies
Figure 6.15 Merck: Key Focus Areas
Figure 6.16 Pfizer: Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 6.17 Pfizer: Key Strategies
Figure 6.18 Pfizer: Key Focus Areas
Figure 6.19 Company Profiles: Concluding Remarks
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.6 Partnerships and Collaborations: Distribution by Company Size
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 7.8 Partnerships and Collaborations: Local and International Agreements
Figure 7.9 Partnerships and Collaborations: Distribution by Geography
Figure 7.10 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 7.11 Most Active Players: Distribution by Number of Partnerships
Figure 7.12 Partnerships and Collaborations: Concluding Remarks
Figure 8.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 8.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.4 Clinical Trial Analysis: Distribution by Type of Patient Population (based on Gender)
Figure 8.5 Clinical Trial Analysis: Key Focus Areas
Figure 8.6 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 8.7 Clinical Trial Analysis: Distribution by Geography
Figure 8.8 Clinical Trial Analysis: Distribution by Trial Status and Geography
Figure 8.9 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 8.10 Clinical Trial Analysis: Distribution of Patient Population by Trial Status and Geography
Figure 8.11 Most Active Industry Players: Analysis by Number of Trials
Figure 8.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 9.1 KOL Analysis: Distribution by Type of KOL
Figure 9.2 KOL Analysis: Distribution by Qualification
Figure 9.3 KOL Analysis: Distribution by Type of Organization
Figure 9.4 KOL Analysis: Distribution by Affiliated Organization
Figure 9.5 KOL Analysis: Distribution by Geographical Location of KOLs
Figure 9.6 KOL Analysis: Distribution by Target Disease Indication(s)
Figure 9.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 9.8 Most Prominent KOLs: Peer Group 1 (Other Types of Investigators)
Figure 9.9 Most Prominent KOLs: Distribution by RA score
Figure 9.10 Most Prominent KOLs: Comparison of RA Score and Third-Party Score
Figure 9.11 KOL Analysis: Concluding Remarks
Figure 10.1. Drug-Pricing Analysis: Distribution by Geography
Figure 10.2. Key Antibiotic Developers: Outsourcing Trends
Figure 11.1. Dovprela (TB Alliance): Success Protocol Analysis
Figure 11.2. Fetroja (Shionogi): Success Protocol Analysis
Figure 11.3 Kimyrsa (Melinta Therapeutics): Success Protocol Analysis
Figure 11.4 Recarbrio (Merck): Success Protocol Analysis
Figure 11.5 Quofenix (Menarini): Success Protocol Analysis
Figure 11.6 Xenleta (Nabriva Therapeutics): Success Protocol Analysis
Figure 11.7 Success Protocol Analysis: Concluding Remarks
Figure 12.1 Global Antibiotics Market, 2023-2030 (USD Billion)
Figure 12.2 Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2030 (USD Billion)
Figure 12.3 Antibiotics Market for Aminoglycosides, 2023-2030 (USD Billion)
Figure 12.4 Antibiotics Market for Cephalosporins, 2023-2030 (USD Billion)
Figure 12.5 Antibiotics Market for Fluoroquinolones, 2023-2030 (USD Billion)
Figure 12.6 Antibiotics Market for Macrolides, 2023-2030 (USD Billion)
Figure 12.7 Antibiotics Market for Oxazolidinones, 2023-2030 (USD Billion)
Figure 12.8 Antibiotics Market for Penicillins, 2023-2030 (USD Billion)
Figure 12.9 Antibiotics Market for Sulphonamides, 2023-2030 (USD Billion)
Figure 12.10 Antibiotics Market for Tetracyclines, 2023-2030 (USD Billion)
Figure 12.11 Antibiotics Market for Other Classes, 2023-2030 (USD Billion)
Figure 12.12 Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2030 (USD Billion)
Figure 12.13 Antibiotics Market for Bacterial Infections, 2023-2030 (USD Billion)
Figure 12.14 Antibiotics Market for Dermatological/ Skin Infections, 2023-2030 (USD Billion)
Figure 12.15 Antibiotics Market for Gastrointestinal Infections, 2023-2030 (USD Billion)
Figure 12.16 Antibiotics Market for Nephrological Infections, 2023-2030 (USD Billion)
Figure 12.17 Antibiotics Market for Pulmonary Infections, 2023-2030 (USD Billion)
Figure 12.18 Antibiotics Market for Reproductive Tract Infections, 2023-2030 (USD Billion)
Figure 12.19 Antibiotics Market for Respiratory Tract Infections, 2023-2030 (USD Billion)
Figure 12.20 Antibiotics Market for Sexually Transmitted Diseases, 2023-2030 (USD Billion)
Figure 12.21 Antibiotics Market for Urinary Tract Infections, 2023-2030 (USD Billion)
Figure 12.22 Antibiotics Market for Other Bacterial Infections, 2023-2030 (USD Billion)
Figure 12.23 Antibiotics Market: Distribution by Type of Therapy, 2023 and 2030 (USD Billion)
Figure 12.24 Antibiotics Market for Monotherapies, 2023-2030 (USD Billion)
Figure 12.25 Antibiotics Market for Combination Therapies, 2023-2030 (USD Billion)
Figure 12.26 Antibiotics Market: Distribution by Route of Administration, 2023 and 2030 (USD Billion)
Figure 12.27 Antibiotics Market for Intravenous Therapies, 2023-2030 (USD Billion)
Figure 12.28 Antibiotics Market for Oral Therapies, 2023-2030 (USD Billion)
Figure 12.29 Antibiotics Market: Distribution by Geography, 2023 and 2030 (USD Billion)
Figure 12.30 Antibiotics Market in North America, 2023-2030 (USD Billion)
Figure 12.31 Antibiotics Market in Europe, 2023-2030 (USD Billion)
Figure 12.32 Antibiotics Market in Asia-Pacific, 2023-2030 (USD Billion)
Figure.13.33 Antibiotics Market in Rest of the World, 2023-2030 (USD Billion)
Figure.13.34 Aemcolo®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.35 Arikayce®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.36 Baxdela™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.37 Dalacin C: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.38 Dovprela®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.39 Emrok: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.40 Emrok-O: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.41 Fetroja®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.42 Kimyrsa™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.43 Lasvic®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.44 Nuzyra®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.45 Orbactiv™/Tenkasi: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.46 Ozanex™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.47 Quofenix: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.48 Recarbrio™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.49 Seysara™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.50 Solosec®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.51 Vabomere™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.52 Xenleta™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.53 XEPI™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.54 Xerava™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.55 Xydalba®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.56 Youxitai: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.57 Zemdri™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.58 Zerbaxa®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.59 Zyvoxam®: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.60 Cefepime-Taniborbactam: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.61 CONTEPO™: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.62 Gepotidacin (GSK2140944): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.63 MBK-01: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.64 MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.65 Nafithromycin (WCK 4873): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.66 RHB-104 (rifabutin, rifabutin, and clofazimin): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.67. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.68 Ridinilazole (SMT 19969): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.69 Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.70 Tebipenem HBr: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.71 WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.72 WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.73 XNW4107 (Funobactam): Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.74 Zabofloxacin: Sales Forecast, 2023-2030 (USD Billion)
Figure. 13.75 Zoliflodacin (ETX0914): Sales Forecast, 2023-2030 (USD Billion)

List Of Tables

Table 3.1 Approved Antibiotic Generics: Information on Year of Approval, Region(s) of Approval, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action, and Spectrum of Activity
Table 3.2 Approved Antibiotic Generics: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Nature of Source and Type of Therapy
Table 3.3 Approved Antibiotic Generics: Information on Route(s) of Administration. Dosage Form(s), and Type of Patient Population (based on Age and Gender)
Table 3.4 Approved Antibiotic Generics: List of Developers
Table 4.1 Approved Antibiotic Brands: Information on Year of Approval, Region(s) of Approval, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action and Spectrum of Activity
Table 4.2 Approved Antibiotic Brands: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Nature of Source and Type of Therapy
Table 4.3 Approved Antibiotic Brands: Information on Route(s) of Administration, Dosage Form(s), Type of Patient Population (based on Age and Gender) and Type of Innovation
Table 4.4 Approved Antibiotic Brands: List of Developers
Table 5.1 Clinical -Stage Antibiotics: Information on Status of Development, Stage of Development, Type of Antibiotic (based on Chemical Structure and Drug Class), Mechanism of Action and Spectrum of Activity
Table 5.2 Clinical -Stage Antibiotics: Information on Type of Target Bacteria(s), Target Bacterial Strain(s), Target Disease Indication(s), Therapeutic Area, Nature of Source and Type of Therapy
Table 5.3 Clinical -Stage Antibiotics: Information on Route(s) of Administration,Dosage Form(s), Dosage Strength, Dosage Frequency and Dosing Period
Table 5.4 Clinical -Stage Antibiotics: Information on Type of Patient Population (based on Age and Gender)
Table 5.5 Clinical -Stage Antibiotics: List of Developers
Table 6.1 Bristol-Myers Squibb: Product Portfolio
Table 6.2 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.3 Daiichi Sankyo: Product Portfolio
Table 6.4 Daiichi Sankyo: Recent Developments and Future Outlook
Table 6.5 GlaxoSmithKline: Product Portfolio
Table 6.6 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.7 Melinta Therapeutics: Product Portfolio
Table 6.8 Melinta Therapeutics: Recent Developments and Future Outlook
Table 6.9 Merck: Product Portfolio
Table 6.10 Merck: Recent Developments and Future Outlook
Table 6.11 Pfizer: Product Portfolio
Table 6.12 Pfizer: Recent Developments and Future Outlook
Table 7.1 Antibiotics: List of Partnerships and Collaborations
Table 8.1. Antibiotics: List of Clinical Trials
Table 9.1. Antibiotics: List of Key Opinion Leaders (KOLs)
Table 10.1. Antibiotics Industry: List of Recent Expansions
Table 11.1 Sales Forecast: List of Approved Antibiotics
Table 12.1 Sales Forecast: List of Clinical-stage Antibiotics
Table 13.1 Approved Antibiotic Generics: Distribution by Year of Approval
Table 13.2 Approved Antibiotic Generics: Distribution by Region(s) of Approval
Table 13.3 Approved Antibiotic Generics: Distribution by Year and Region(s) of Approval
Table 13.4 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.5 Approved Antibiotic Generics: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.6 Approved Antibiotic Generics: Distribution by Mechanism of Action
Table 13.7 Approved Antibiotic Generics: Distribution by Spectrum of Activity
Table 13.8 Approved Antibiotic Generics: Distribution by Type of Target Bacteria(s)
Table 13.9 Approved Antibiotic Generics: Distribution by Target Bacterial Strain(s)
Table 13.10 Approved Antibiotic Generics: Distribution by Target Disease Indication(s)
Table 13.11 Approved Antibiotic Generics: Distribution by Nature of Source
Table 13.12 Approved Antibiotic Generics: Distribution by Type of Therapy
Table 13.13 Approved Antibiotic Generics: Distribution by Route(s) of Administration
Table 13.14 Approved Antibiotic Generics: Distribution by Dosage Form(s)
Table 13.15 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Age)
Table 13.16 Approved Antibiotic Generics: Distribution by Type of Patient Population (based on Gender)
Table 13.17 Approved Antibiotic Generic Developers: Distribution by Year of Establishment
Table 13.18 Approved Antibiotic Generic Developers: Distribution by Company Size
Table 13.19 Approved Antibiotic Generic Developers: Distribution by Location of Headquarters
Table 13.20 Most Active Players: Distribution by Number of Approved Generics
Table 13.21 Approved Antibiotic Brands: Distribution by Year of Approval
Table 13.22 Approved Antibiotic Brands: Distribution by Region(s) of Approval
Table 13.23 Approved Antibiotic Brands: Distribution by Year and Region(s) of Approval
Table 13.24 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.25 Approved Antibiotic Brands: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.26 Approved Antibiotic Brands: Distribution by Mechanism of Action
Table 13.27 Approved Antibiotic Brands: Distribution by Spectrum of Activity
Table 13.28 Approved Antibiotic Brands: Distribution by Type of Target Bacteria(s)
Table 13.29 Approved Antibiotic Brands: Distribution by Target Bacterial Strain(s)
Table 13.30 Approved Antibiotic Brands: Distribution by Target Disease Indication(s)
Table 13.31 Approved Antibiotic Brands: Distribution by Nature of Source
Table 13.32 Approved Antibiotic Brands: Distribution by Type of Therapy
Table 13.33 Approved Antibiotic Brands: Distribution by Route(s) of Administration
Table 13.34 Approved Antibiotic Brands: Distribution by Dosage Form(s)
Table 13.35 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Age)
Table 13.36 Approved Antibiotic Brands: Distribution by Type of Patient Population (based on Gender)
Table 13.37 Approved Antibiotic Brands: Distribution by Type of Innovation
Table 13.38 Approved Antibiotic Brand Developers: Distribution by Year of Establishment
Table 13.39 Approved Antibiotic Brand Developers: Distribution by Company Size
Table 13.40 Approved Antibiotic Brand Developers: Distribution by Location of Headquarters
Table 13.41 Most Active Players: Distribution by Number of Approved Brands
Table 13.42 Clinical -Stage Antibiotics: Distribution by Status of Development
Table 13.43 Clinical -Stage Antibiotics: Distribution by Stage of Development
Table 13.44 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Chemical Structure)
Table 13.45 Clinical -Stage Antibiotics: Distribution by Type of Antibiotic (based on Drug Class)
Table 13.46 Clinical -Stage Antibiotics: Distribution by Mechanism of Action
Table 13.47 Clinical -Stage Antibiotics: Distribution by Spectrum of Activity
Table 13.48 Clinical -Stage Antibiotics: Distribution by Type of Target Bacteria(s)
Table 13.49 Clinical -Stage Antibiotics: Distribution by Target Bacterial Strain(s)
Table 13.50 Clinical -Stage Antibiotics: Distribution by Target Disease Indication(s)
Table 13.51 Clinical -Stage Antibiotics: Distribution by Therapeutic Area(s)
Table 13.52 Clinical -Stage Antibiotics: Distribution by Nature of Source
Table 13.53 Clinical -Stage Antibiotics: Distribution by Type of Therapy
Table 13.54 Clinical -Stage Antibiotics: Distribution by Route(s) of Administration
Table 13.55 Clinical -Stage Antibiotics: Distribution by Dosage Form(s)
Table 13.56 Clinical -Stage Antibiotics: Distribution by Dosage Strength
Table 13.57 Clinical -Stage Antibiotics: Distribution by Dosage Frequency
Table 13.58 Clinical -Stage Antibiotics: Distribution by Dosing Period
Table 13.59 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Age)
Table 13.60 Clinical -Stage Antibiotics: Distribution by Type of Patient Population (based on Gender)
Table 13.61 Clinical -Stage Antibiotics: Distribution by Special Designation Received
Table 13.62 Clinical -Stage Antibiotic Developers: Distribution by Year of Establishment
Table 13.63 Clinical -Stage Antibiotic Developers: Distribution by Company Size
Table 13.64 Clinical -Stage Antibiotic Developers: Distribution by Location of Headquarters
Table 13.65 Most Active Players: Analysis by Number of Clinical-stage Antibiotics
Table 13.66 Most Active Players: Analysis by Number of Preclinical-stage Antibiotics
Table 13.67 Partnerships and Collaborations: Distribution by Year of Partnership
Table 13.68 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.69 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 13.70 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.71 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 13.72 Partnerships and Collaborations: Distribution by Company Size
Table 13.73 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 13.74 Partnerships and Collaborations: Local and International Agreements
Table 13.75 Partnerships and Collaborations: Distribution by Geography
Table 13.76 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 13.77 Most Active Players: Distribution by Number of Partnerships
Table 13.78 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 13.79 Clinical Trial Analysis: Distribution by Trial Status
Table 13.80 Clinical Trial Analysis: Distribution by Trial Phase
Table 13.81 Clinical Trial Analysis: Distribution by Type of Patient Population (based on Gender)
Table 13.82 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 13.83 Clinical Trial Analysis: Distribution by Geography
Table 13.84 Clinical Trial Analysis: Distribution by Trial Status and Geography
Table 13.85 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 13.86 Clinical Trial Analysis: Distribution of Patient Population by Trial Status and Geography
Table 13.87 Most Active Industry Players: Analysis by Number of Trials
Table 13.88 Most Active Non-Industry Players: Analysis by Number of Trials
Table 13.89 KOL Analysis: Distribution by Type of KOL
Table 13.90 KOL Analysis: Distribution by Qualification
Table 13.91 KOL Analysis: Distribution by Type of Organization
Table 13.92 KOL Analysis: Distribution by Affiliated Organization
Table 13.93 KOL Analysis: Distribution by Geographical Location of KOLs
Table 13.94 KOL Analysis: Distribution by Target Disease Indication(s)
Table 13.95 Global Antibiotics Market: Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.96 Antibiotics Market: Distribution by Type of Antibiotic (based on Drug Class), 2023 and 2030 (USD Billion)
Table 13.97 Antibiotics Market for Aminoglycosides, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.98 Antibiotics Market for Cephalosporins, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.99 Antibiotics Market for Fluoroquinolones, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.100 Antibiotics Market for Macrolides, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.101 Antibiotics Market for Oxazolidinones, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.102 Antibiotics Market for Penicillins, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.103 Antibiotics Market for Sulphonamides, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.104 Antibiotics Market for Tetracyclines, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.105 Antibiotics Market for Other Classes, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.106 Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2030 (USD Billion)
Table 13.107 Antibiotics Market for Bacterial Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.108 Antibiotics Market for Dermatological/ Skin Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.109 Antibiotics Market for Gastrointestinal Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.110 Antibiotics Market for Nephrological Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.111 Antibiotics Market for Pulmonary Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.112 Antibiotics Market for Reproductive Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.113 Antibiotics Market for Respiratory Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.114 Antibiotics Market for Sexually Transmitted Diseases, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.115 Antibiotics Market for Urinary Tract Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.116 Antibiotics Market for Other Bacterial Infections, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.117 Antibiotics Market: Distribution by Type of Therapy, 2023 and 2030 (USD Billion)
Table 13.118 Antibiotics Market for Monotherapies, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.119 Antibiotics Market for Combination Therapies, 2023-2030 (USD Billion)
Table 13.120 Antibiotics Market: Distribution by Route of Administration, 2023 and 2030 (USD Billion)
Table 13.121 Antibiotics Market for Intravenous Therapies, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.122 Antibiotics Market for Oral Therapies, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.123 Antibiotics Market: Distribution by Geography, 2023 and 2030
Table 13.124 Antibiotics Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.125 Antibiotics Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.126 Antibiotics Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.127 Antibiotics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.128 Aemcolo®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.129 Arikayce®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.130 Baxdela™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion))
Table 13.131 Dalacin C: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.132 Dovprela®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.133 Emrok: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.134 Emrok-O: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.135 Fetroja®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.136 Kimyrsa™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.137 Lasvic®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.138 Nuzyra®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.139 Orbactiv™/Tenkasi: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.140 Ozanex™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.141 Quofenix: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.142 Recarbrio™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.143 Seysara™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.144 Solosec®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.145 Vabomere™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.146 Xenleta™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.147 XEPI™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.148 Xerava™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.149 Xydalba®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.150 Youxitai: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.151 Zemdri™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.152 Zerbaxa®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.153 Zyvoxam®: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.154 Cefepime-Taniborbactam: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.155 CONTEPO™: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.156 Gepotidacin (GSK2140944): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.157 MBK-01: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.158 MRX-4 (Contezolid Acefosamil): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.159 Nafithromycin (WCK 4873): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.160 RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.161 RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.162 Ridinilazole (SMT 19969): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.163 Sulopenem- etzadroxil- probenecid: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.164 Tebipenem HBr: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.165 WCK 4282 (Cefepime-Tazobactam): Sales Forecast, , Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.166 WCK 5222 (cefepime + zidebactam): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.167 XNW4107 (Funobactam): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.168 Zabofloxacin: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)
Table 13.169 Zoliflodacin (ETX0914): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2030 (USD Billion)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. Abbott
2. ABAC Therapeutics
3. AbbVie
4. Aceragen
5. Acurx Pharmaceuticals
6. Affinivax (a subsidiary of GlaxoSmithKline) 
7. AGILeBiotics 
8. Alcon
9. Alfa Wassermann
10. Allecra Therapeutics
11. Angelini Pharma
12. Antimicrobials Working Group (AWG)
13. Aptuit
14. Ares Genetics (acquired by OpGen)
15. Arrevus (a subsidiary of Aceragen)
16. Astellas Pharma (formerly known as Fujisawa Pharmaceutical)
17. B. Braun
18. Basilea Pharmaceutica
19. Bayer
20. Bill & Melinda Gates Foundation
21. Bill & Melinda Gates Medical Research Institute
22. BIOASTER
23. Biocidium Biopharmaceuticals
24. bioMérieux
25. BioVersys 
26. Blacksmith Medicines
27. Boulos and Cooper Pharmaceuticals
28. Brii Biosciences
29. Bristol-Myers Squibb
30. Bugworks Research
31. Calibr
32. Cardiome Pharma
33. Catalent
34. Chia Tai Tianqing Pharmaceutical
35. Cipla
36. Colgate-Palmolive
37. Commonwealth Scientific and Industrial Research Organization
38. ContraFect
39. Cosmo Pharmaceuticals
40. Cosmo Technologies
41. Crestone
42. CrystalGenomics
43. Cubist Pharmaceuticals
44. Curetis
45. Daiichi Sankyo
46. Damascus Hospital
47. Debiopharm
48. Defense Threat Reduction Agency (DTRA)
49. DEINOVE
50. Department of Health and Human Services
51. Discuva (a subsidiary of Summit Therapeutics) 
52. Dongwha Pharmaceutical
53. Entasis Therapeutics
54. Er-Kim Pharmaceuticals
55. Eurofarma
56. Everest Medicines
57. EVERSANA
58. Evotec
59. Exeltis
60. Fedora Pharmaceuticals
61. Ferrer Internacional
62. Forest Laboratories
63. Forge Therapeutics (a subsidiary of Blacksmith Medicines)
64. Fosun Pharma
65. Foundation for Neglected Disease Research (FNDR)
66. French National Agency for the Safety of Medicines and Health Products (ANSM)
67. Fresenius Kabi
68. Fujifilm
69. Genentech
70. Gilead Sciences
71. GlaxoSmithKline
72. Global Antibiotic Research and Development Partnership (GARDP)
73. HanaVax
74. Hartford Healthcare
75. Helperby Therapeutics
76. Helsinki University Hospital
77. Hikma Pharmaceuticals
78. Hoffmann-La Roche
79. Hsiri Therapeutics
80. Huazhong University of Science and Technology
81. HUTCHMED
82. Idera Pharmaceuticals
83. Infex Therapeutics
84. Innoviva
85. Insmed
86. Institut Pasteur de Lille
87. InveniAI
88. Iterum Therapeutics
89. Janssen Pharmaceutical
90. JEIL Pharmaceutical
91. Juvabis
92. KBP Biosciences
93. Kyorin Pharmaceutical
94. Kyoto Pharmaceutical
95. Kyowa Hakko Bio
96. La Jolla Pharmaceutical Company
97. LANCET Pharmaceuticals
98. LegoChem Biosciences
99. LifeArc

100. Liverpool School of Tropical Medicine
101. Lupin
102. MacKay Memorial Hospital
103. Macleods Pharmaceuticals
104. Madam Therapeutics
105. Mahidol University
106. Maruho 
107. Medical College of Wisconsin
108. Medicines for Malaria Venture (MMV)
109. Medimetriks Pharmaceuticals
110. Medpace
111. Meiji Seika Pharma
112. Melinta Therapeutics
113. Merck
114. MGB Biopharma
115. MicuRx Pharmaceuticals
116. Mikrobiomik
117. Mitsubishi Tanabe Pharma

Research Methodology